AZD-1656 is under clinical development by Conduit Pharmaceuticals and currently in Phase I for Uveitis. According to GlobalData, Phase I drugs for Uveitis have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AZD-1656’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AZD-1656 overview

AZD-1656 is under development for the treatment of post-renal transplant type 2 diabetes, Hashimoto's  thyroiditis, Graves disease, kidney transplant rejection, uveitis, anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA Vasculitis) and preterm labor. It is administered through oral route in the form of film coated tablet. It acts by targeting the glucokinase (GK). It is a new chemical entity. 

The drug candidate was under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Conduit Pharmaceuticals overview

Conduit Pharmaceuticals is a biopharmaceutical company that is involved in developing AZD5904 (myeloperoxidase inhibitor) and AZD1656 (glucokinase activator) for the treatment of idiopathic male infertility and autoimmune diseases or immunodeficient conditions such as uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. It is headquartered in San Diego, California, the US.

For a complete picture of AZD-1656’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.